Literature DB >> 8261393

Microsatellite instability is associated with tumors that characterize the hereditary non-polyposis colorectal carcinoma syndrome.

P Peltomäki1, R A Lothe, L A Aaltonen, L Pylkkänen, M Nyström-Lahti, R Seruca, L David, R Holm, D Ryberg, A Haugen.   

Abstract

Microsatellite instability implying multiple replication errors (RER+ phenotype) characterizes a proportion of colorectal carcinomas, particularly those from patients with the hereditary non-polyposis colorectal carcinoma syndrome. We studied the incidence of microsatellite instability in more than 500 sporadic tumors representing 6 different types of cancer. Apart from colorectal carcinoma [see the paper by Lothe et al. (Cancer Res., 53:5849-5852, 1993)] the RER+ phenotype was found in 18% (6 of 33) of gastric carcinomas and 22% (4 of 18) of endometrial carcinomas. In contrast, no evidence of this abnormality was detected in cancers of the lung (N = 85), breast (N = 84), and testis (N = 86). Importantly, the first three cancers, as opposed to the latter three, are characteristic of the hereditary non-polyposis colorectal carcinoma syndrome. These findings suggest that the cancers belonging to the hereditary non-polyposis colorectal carcinoma tumor spectrum may have essential pathogenetic steps in common, including a tendency to multiple replication errors.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8261393

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  113 in total

1.  Microsatellite instability.

Authors:  I M Frayling
Journal:  Gut       Date:  1999-07       Impact factor: 23.059

2.  Analysis of the frequency of microsatellite instability and p53 gene mutation in splenic marginal zone and MALT lymphomas.

Authors:  M Sol Mateo; M Mollejo; R Villuendas; P Algara; M Sánchez-Beato; B Martinez-Delgado; P Martínez; M A Piris
Journal:  Mol Pathol       Date:  1998-10

3.  Microsatellite instability, MMR gene expression and proliferation kinetics in colorectal cancer with famillial predisposition.

Authors:  Bao-Ping Wu; Ya-Li Zhang; Dian-Yuan Zhou; Chun-Fang Gao; Zhuo-Sheng Lai
Journal:  World J Gastroenterol       Date:  2000-12       Impact factor: 5.742

4.  Amplification of mutator cells in a population as a result of horizontal transfer.

Authors:  P Funchain; A Yeung; J Stewart; W M Clendenin; J H Miller
Journal:  J Bacteriol       Date:  2001-06       Impact factor: 3.490

5.  The revised Bethesda guidelines: extent of utilization in a university hospital medical center with a cancer genetics program.

Authors:  Aparna Mukherjee; Thomas J McGarrity; Francesca Ruggiero; Walter Koltun; Kevin McKenna; Lisa Poritz; Maria J Baker
Journal:  Hered Cancer Clin Pract       Date:  2010-11-22       Impact factor: 2.857

6.  Risk of endometrial cancer for women diagnosed with HNPCC-related colorectal carcinoma.

Authors:  Andreas Obermair; Danny R Youlden; Joanne P Young; Noralane M Lindor; John A Baron; Polly Newcomb; Susan Parry; John L Hopper; Robert Haile; Mark A Jenkins
Journal:  Int J Cancer       Date:  2010-12-01       Impact factor: 7.396

7.  The "comparative growth assay": examining the interplay of anti-cancer agents with cells carrying single gene alterations.

Authors:  P Hausner; D J Venzon; L Grogan; I R Kirsch
Journal:  Neoplasia       Date:  1999-10       Impact factor: 5.715

8.  Direct selection for mutators in Escherichia coli.

Authors:  J H Miller; A Suthar; J Tai; A Yeung; C Truong; J L Stewart
Journal:  J Bacteriol       Date:  1999-03       Impact factor: 3.490

Review 9.  Microsatellite instability in colorectal cancer.

Authors:  C Richard Boland; Ajay Goel
Journal:  Gastroenterology       Date:  2010-06       Impact factor: 22.682

10.  DNA polymerase delta, RFC and PCNA are required for repair synthesis of large looped heteroduplexes in Saccharomyces cerevisiae.

Authors:  Stephanie E Corrette-Bennett; Claudia Borgeson; Debbie Sommer; Peter M J Burgers; Robert S Lahue
Journal:  Nucleic Acids Res       Date:  2004-12-01       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.